RANDAL J KIRK Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for RANDAL J KIRK.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of RANDAL J KIRK. RANDAL J KIRK is 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in Synthetic Biologics, Inc. ($SYN) and 10% Owner in TRANSGENOMIC INC ($TBIO) and Director in ZIOPHARM ONCOLOGY INC ($ZIOP) and Director in HALOZYME THERAPEUTICS INC ($GYHT) and 10% Owner in ORAGENICS INC ($OGEN) and 10% Owner in INTREXON CORP ($XON) and Chief Executive Officer in INTREXON CORP ($XON) and Director in INTREXON CORP ($XON).
Latest Insider Trading Transactions of RANDAL J KIRK
Sentiment: All, FCSC, GYHT, OGEN, XON, PRPO, SYN, ZIOP
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 29 2013 | TBIO | TRANSGENOMIC INC | KIRK RANDAL J | 10% Owner | Buy | P | 0.00 | 1,200,000 | 0 | 1,849,181 | 649.2 K to 1.8 M (+184.85 %) |
| Jan 29 2013 | TBIO | TRANSGENOMIC INC | KIRK RANDAL J | 10% Owner | Buy | P | 0.00 | 2,400,000 | 0 | 3,698,361 | 1.3 M to 3.7 M (+184.85 %) |
| Jan 29 2013 | TBIO | TRANSGENOMIC INC | KIRK RANDAL J | 10% Owner | Buy | P | 0.00 | 2,400,000 | 0 | 3,698,361 | 1.3 M to 3.7 M (+184.85 %) |
| Nov 09 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 0.00 | 3,636,926 | 0 | 13,533,162 | 9.9 M to 13.5 M (+36.75 %) |
| Oct 31 2012 | SYN | Synthetic Biologic ... | KIRK RANDAL J | 10% Owner | Buy | P | 1.60 | 3,125,000 | 5,000,000 | 3,125,000 | 0 to 3.1 M |
| Nov 09 2012 | XON | INTREXON CORP | KIRK RANDAL J | Director | Buy | P | 0.00 | 3,636,926 | 0 | 13,533,162 | 9.9 M to 13.5 M (+36.75 %) |
| Oct 31 2012 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | P | 1.60 | 3,125,000 | 5,000,000 | 3,125,000 | 0 to 3.1 M |
| Aug 02 2012 | OGEN | ORAGENICS INC | KIRK RANDAL J | 10% Owner | Buy | P | 1.50 | 857,555 | 1,286,333 | 857,555 | 0 to 857.6 K |
| Aug 02 2012 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | P | 1.50 | 857,555 | 1,286,333 | 857,555 | 0 to 857.6 K |
| Jun 05 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.48 | 2,731 | 20,428 | 331,394 | 328.7 K to 331.4 K (+0.83 %) |
| Jun 05 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.48 | 2,732 | 20,435 | 331,395 | 328.7 K to 331.4 K (+0.83 %) |
| Jun 05 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.37 | 44,823 | 330,346 | 328,663 | 283.8 K to 328.7 K (+15.79 %) |
| Jun 05 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.37 | 44,823 | 330,346 | 328,663 | 283.8 K to 328.7 K (+15.79 %) |
| Jun 05 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.39 | 49,540 | 366,101 | 283,840 | 234.3 K to 283.8 K (+21.14 %) |
| Jun 05 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.39 | 49,540 | 366,101 | 283,840 | 234.3 K to 283.8 K (+21.14 %) |
| May 17 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.50 | 299,007 | 2,242,553 | 3,977,445 | 3.7 M to 4 M (+8.13 %) |
| May 17 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.44 | 344,910 | 2,566,130 | 3,678,438 | 3.3 M to 3.7 M (+10.35 %) |
| May 17 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.35 | 427,581 | 3,142,720 | 3,333,528 | 2.9 M to 3.3 M (+14.71 %) |
| May 07 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 20,000 | 0 | 3,450,000 | 3.4 M to 3.5 M (+0.58 %) |
| Feb 07 2012 | TBIO | TRANSGENOMIC INC | KIRK RANDAL J | 10% Owner | Option Exercise | C | 1.25 | 300,000 | 375,000 | 300,000 | |
| Feb 07 2012 | TBIO | TRANSGENOMIC INC | KIRK RANDAL J | 10% Owner | Option Exercise | C | 1.25 | 600,000 | 750,000 | 600,000 | |
| Feb 07 2012 | TBIO | TRANSGENOMIC INC | KIRK RANDAL J | 10% Owner | Option Exercise | C | 1.25 | 600,000 | 750,000 | 600,000 | |
| Feb 07 2012 | TBIO | TRANSGENOMIC INC | KIRK RANDAL J | 10% Owner | Buy | C | 0.00 | 600,000 | 0 | 649,181 | 49.2 K to 649.2 K (+1,219.98 %) |
| Feb 07 2012 | TBIO | TRANSGENOMIC INC | KIRK RANDAL J | 10% Owner | Buy | C | 0.00 | 1,200,000 | 0 | 1,298,361 | 98.4 K to 1.3 M (+1,220.00 %) |
| Feb 07 2012 | TBIO | TRANSGENOMIC INC | KIRK RANDAL J | 10% Owner | Buy | C | 0.00 | 1,200,000 | 0 | 1,298,361 | 98.4 K to 1.3 M (+1,220.00 %) |
| Feb 13 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 10.61 | 185,000 | 1,962,850 | 234,300 | 49.3 K to 234.3 K (+375.25 %) |
| Feb 13 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 10.61 | 185,000 | 1,962,850 | 234,300 | 49.3 K to 234.3 K (+375.25 %) |
| Feb 13 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 10.61 | 990,000 | 10,503,900 | 2,905,947 | 1.9 M to 2.9 M (+51.67 %) |
| Nov 09 2011 | TBIO | TRANSGENOMIC INC | KIRK RANDAL J | 10% Owner | Buy | J | 1.22 | 49,181 | 60,001 | 49,181 | 0 to 49.2 K |
| Nov 09 2011 | TBIO | TRANSGENOMIC INC | KIRK RANDAL J | 10% Owner | Buy | J | 1.22 | 98,361 | 120,000 | 98,361 | 0 to 98.4 K |
| Nov 09 2011 | TBIO | TRANSGENOMIC INC | KIRK RANDAL J | 10% Owner | Buy | J | 1.22 | 98,361 | 120,000 | 98,361 | 0 to 98.4 K |
| Nov 23 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 8.00 | 166,100 | 1,328,800 | 1,915,947 | 1.7 M to 1.9 M (+9.49 %) |
| Nov 23 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 8.11 | 55,146 | 447,234 | 1,749,847 | 1.7 M to 1.7 M (+3.25 %) |
| Nov 23 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 8.04 | 56,477 | 454,075 | 1,694,701 | 1.6 M to 1.7 M (+3.45 %) |
| Nov 16 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 8.19 | 175,520 | 1,437,509 | 1,638,224 | 1.5 M to 1.6 M (+12.00 %) |
| Nov 16 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 8.18 | 242,704 | 1,985,319 | 1,462,704 | 1.2 M to 1.5 M (+19.89 %) |
| Nov 16 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 8.13 | 220,000 | 1,788,600 | 1,220,000 | 1000 K to 1.2 M (+22.00 %) |
| Aug 11 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 6.13 | 261,669 | 1,604,031 | 1,000,000 | 738.3 K to 1000 K (+35.44 %) |
| Aug 11 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.88 | 738,331 | 4,341,386 | 738,331 | 0 to 738.3 K |
| Feb 07 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 5.75 | 1,910,000 | 10,982,500 | 7,973,161 | 6.1 M to 8 M (+31.50 %) |
| Jan 14 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | A | 5.21 | 25,000 | 130,250 | 25,000 | |
| Jan 14 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 0.00 | 3,636,926 | 0 | 6,063,161 | 2.4 M to 6.1 M (+149.90 %) |
| Jan 14 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 4.80 | 2,426,235 | 11,645,928 | 2,426,235 | 0 to 2.4 M |
| Jan 14 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
| Feb 07 2011 | XON | INTREXON CORP | KIRK RANDAL J | Director | Buy | P | 5.75 | 1,910,000 | 10,982,500 | 7,973,161 | 6.1 M to 8 M (+31.50 %) |